POMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Medstar Health Research Institute
Study ID
NCT06634459
Status
Recruiting

Conditions

  • Pelvic Organ Prolapse
  • Prolapse

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Reia System — DEVICE
    Reia pessary
  • Standard of Care Pessary — DEVICE
    Gellhorn pessary or ring with/without support without knob pessary

Study Details

This multi-centered, randomized controlled trial will evaluate the safety and efficacy of home use of the novel Reia System (RS), which includes the Reia pessary and applicator, compared to standard pessary care (Gellhorn or ring with/without support without knob) among women with stage II-IV pelvic organ prolapse (POP). A total of 200 participants will be recruited among pessary naïve patients who are symptomatic and choose a vaginal pessary for management of their POP from study sites specializing in Urogynecology and Reconstructive Pelvic Surgery (URPS). Participants will be assigned via 1:1 randomization using computer generated numbers in permutated groups of variable block sizes to either the intervention (the Reia System, RS) or standard pessary care (SPC) stratified by site. Participation in this trial will involve a total of four visits over six months. The primary outcome measure will be satisfaction measured at the six-month time point. Secondary outcomes will include validated surveys to assess quality of life, number of self-management events, ease/difficulty of pessary insertion/removal, importance of ability to self-manage pessary, and adverse events. Specific Aims Aim 1: To compare satisfaction with pessary use and management between subjects randomized to the Reia System and those randomized to standard of care pessary. Aim 2: To assess successful fitting, number of refitting visits, number of self-management events and continued pessary use over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary. Aim 3: To compare ease/difficulty of pessary use and importance of ability to self-manage, as well as quality of life over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary. Aim 4: To measure rates of adverse events and risk factors for adverse events over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary.

Key Dates

Start date
Nov 1, 2024
Status verified
Jun 2025
Primary completion
Apr 30, 2026
Completion
Oct 30, 2026

Study Design

Enrollment
218 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Reia System
    Participants receiving the commercially available RS will be fit with one of three available pessary sizes and will receive an applicator corresponding to their pessary size.
  • Active Comparator: Standard Pessary Care
    Participants receiving SPC will be fit with a Gellhorn pessary or ring with/without support without knob pessary per standard clinical protocol.

Primary Outcome Measure

Satisfaction with treatment [ Time Frame: 6 months ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35249
Donna Cox
205-934-1775
Gabriela Halder, MD (PRINCIPAL_INVESTIGATOR)
Holly Richter, MD (SUB_INVESTIGATOR)
David Ellington, MD (SUB_INVESTIGATOR)
Gena Dunivan, MD (SUB_INVESTIGATOR)
Thomas Powell, MD (SUB_INVESTIGATOR)
Stanford UniversityPalo AltoCalifornia94304
Kathryn Batham
650-724-7826
Eric Sokol, MD (PRINCIPAL_INVESTIGATOR)
MedStar HealthWashington D.C.District of Columbia20010
Kendra Green
202-997-4536
Alexis Dieter, MD (PRINCIPAL_INVESTIGATOR)
Robert Gutman, MD (SUB_INVESTIGATOR)
Cheryl Iglesia, MD (SUB_INVESTIGATOR)
Lee Ann Richter, MD (SUB_INVESTIGATOR)
Andrew Sokol, MD (SUB_INVESTIGATOR)
The University of ChicagoNorthbrookIllinois60062
Jinxuan (Rowena) Shi
773-795-2731
Margaret Mueller, MD (PRINCIPAL_INVESTIGATOR)
Kimberly Kenton, MD (SUB_INVESTIGATOR)
Christina Lewicky-Gaupp, MD (SUB_INVESTIGATOR)
Sarah Collins, MD (SUB_INVESTIGATOR)
Juraj Letko, MD (SUB_INVESTIGATOR)
Sandra Valaitis, MD (SUB_INVESTIGATOR)
Douglas Russo, MD (SUB_INVESTIGATOR)
Iris Burgard, MD (SUB_INVESTIGATOR)
Dartmouth-HitchcockLebanonNew Hampshire03756
Grace Wallace
603-653-6808
Kris Strohbehn (PRINCIPAL_INVESTIGATOR)
University of New Mexico Health Sciences CenterAlbuquerqueNew Mexico87131
Madison Gonya
505-272-7539
Atrium Health Wake Forest BaptistWinston-SalemNorth Carolina27103
Sachin Vyas
336-713-4098
Katherine Woodburn (PRINCIPAL_INVESTIGATOR)
Women & Infants Hospital in Rhode IslandProvidenceRhode Island02903
Leah McKay
401-274-1122
University of WisconsinMadisonWisconsin53711
Robin Wasielewski
310-570-9150
Jon Pennycuff (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

Related Studies